SBT8230
SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
TLR8 |
SBT8230 acts as a liver-localized TLR8 agonist targeting ASGR1, activates myeloid cells, and induces anti-HBV immune responses and antiviral T cell responses in hepatic cellular models[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ASGR1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Gan L, et al. A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1. Int J Mol Sci. 2025;26(10):4590. Published 2025 May 10. [Content Brief]
[2]. Mak LY, et al. New strategies for the treatment of chronic hepatitis B. Trends Mol Med. 2022;28(9):742-757. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz